Congenital myasthenic syndromes: increasingly complex
Sithara Ramdas,David Beeson,Yin Yao Dong
DOI: https://doi.org/10.1097/wco.0000000000001300
2024-09-04
Current Opinion in Neurology
Abstract:Congenital myasthenia syndromes (CMS) are caused by genetic defects that impair neuromuscular transmission. Efficient synaptic transmission at the neuromuscular junction (NMJ) incorporates many different proteins involved both in the signal transmission itself and in generating the prerequisite specialized synaptic structures. As a consequence, there are multiple pathogenic mechanisms that can underlie CMS. A recent comprehensive review of CMS highlights many of these mechanisms [1▪▪] . There are currently 35 genes reported to be associated with CMS (Fig. 1 and Table 1). The prevalence reported varies considerably between regions, 2.8–14.8 per million (UK), 1.8 per million (Brazil), and 22.2 per million (Slovenia) [2] . Differences are likely to occur because of mutation founder effects in certain regions and historically because of different pick-up rates as new detection technologies are adopted. The clinical use of next-generation sequencing greatly facilitates detection of mutations in larger genes, such as AGRN , LRP4 , MUSK , COLQ , and thus increases in reported prevalence is likely to continue [3–7] . Whilst symptom onset at birth or infancy is the commonest presentation, later onset in childhood and adult life is now increasingly recognized. The clinical phenotypes can vary in the subtypes, but the hallmark is fatigable weakness predominantly affecting axial and proximal limb muscle, ocular, bulbar and or respiratory involvement. A suspected diagnosis is based on typical clinical features, decremental responses of 10% or more on repetitive nerve stimulation (RNS) and/or abnormal jitter and block on single-fibre EMG. It is prudent to note that RNS may show incremental response on high-frequency stimulation in some presynaptic (VAMP1, UNC13A, SYT2, RPH3A) and one synaptic (LAMA5) CMS subtype [8,9] . The inheritance patten in CMS is autosomal recessive except for dominant pattern seen in slow channel syndromes, SNAP25, PURA and some SYT2 patients [1▪▪] . Here, we highlight the widening phenotype spectrum associated with gene mutations that can not only have an effect of the NMJ but also show systemic and brain involvement (Table 2), and on current and emerging therapeutic strategies for CMS.
neurosciences,clinical neurology